Table 2.

Patients characteristics at the beginning of the study (group B).

Group B	Age (years)	Sex	Diagnosis	Therapy	Dose1	Hb2	Epo3	Cr4
Patient 1	70	M	Colon-rectal cancer	5-Fluorouracil	375	136	14.44	88.4
				Leucovorin	100
Patient 2	52	F	Colon-rectal cancer	5-Fluorouracil	375	118	9.40	84.0
				Leucovorin	100
Patient 3	63	F	Colon-rectal cancer	5-Fluorouracil	375	131	13.94	58.4
				Leucovorin	100
Patient 4	52	F	Colon-rectal cancer	5-Fluorouracil	375	123	21.04	53.0
				Leucovorin	100
Patient 5	79	F	Colon-rectal cancer	5-Fluorouracil	375	142	16.12	66.3
				Leucovorin	100
Patient 6	64	M	Colon-rectal cancer	5-Fluorouracil	375	130	24.78	74.3
				Leucovorin	100
Patient 7	64	M	Head and neck cancer	Vinorelbin	20	128	13.11	66.3
				Docetaxel	80
Patient 8	54	M	Colon-rectal cancer	5-Fluorouracil	2000	152	12.51	61.0
				Mitomicina	15
Patient 9	70	F	Colon-rectal cancer	5-Fluorouracil	375	130	29.51	70.7
				Leucovorin	100
Patient 10	64	M	Colon-rectal cancer	5-Fluorouracil	370	110	33.80	81.4
				Leucovorin	10
Mean						130.00	18.87
Median						130.00	15.28
s.d.					11.84	8.10		11.6

¹Dose mg/m²

²Hb g/l

³Erythropoietin (Epo) mU/ml

⁴Creatinine (Cr) μmol/l.